

Juan V Guanira

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3710496/publications.pdf>

Version: 2024-02-01

32
papers

3,361
citations

304743

22
h-index

454955

30
g-index

32
all docs

32
docs citations

32
times ranked

3294
citing authors

#	ARTICLE	IF	CITATIONS
1	Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 820-829.	9.1	1,039
2	Emtricitabine-Tenofovir Concentrations and Pre-Exposure Prophylaxis Efficacy in Men Who Have Sex with Men. <i>Science Translational Medicine</i> , 2012, 4, 151ra125.	12.4	807
3	HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial. <i>Lancet HIV</i> , the, 2015, 2, e512-e519.	4.7	225
4	Syphilis Predicts HIV Incidence Among Men and Transgender Women Who Have Sex With Men in a Preexposure Prophylaxis Trial. <i>Clinical Infectious Diseases</i> , 2014, 59, 1020-1026.	5.8	132
5	Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial. <i>Clinical Infectious Diseases</i> , 2015, 61, 572-580.	5.8	132
6	HIV pre-exposure prophylaxis in men who have sex with men and transgender women: a secondary analysis of a phase 3 randomised controlled efficacy trial. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 468-475.	9.1	128
7	Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis. <i>Aids</i> , 2014, 28, 851-859.	2.2	123
8	Association of Herpes Simplex Virus Type 2 Infection and Syphilis with Human Immunodeficiency Virus Infection among Men Who Have Sex with Men in Peru. <i>Journal of Infectious Diseases</i> , 2006, 194, 1459-1466.	4.0	91
9	Study Product Adherence Measurement in the iPrEx Placebo-Controlled Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 66, 530-537.	2.1	73
10	HIV-1 Drug Resistance in the iPrEx Preexposure Prophylaxis Trial. <i>Journal of Infectious Diseases</i> , 2014, 210, 1217-1227.	4.0	68
11	Association of age, baseline kidney function, and medication exposure with declines in creatinine clearance on pre-exposure prophylaxis: an observational cohort study. <i>Lancet HIV</i> , the, 2016, 3, e521-e528.	4.7	66
12	Strong Correlation Between Concentrations of Tenofovir (TFV) Emtricitabine (FTC) in Hair and TFV Diphosphate and FTC Triphosphate in Dried Blood Spots in the iPrEx Open Label Extension: Implications for Pre-exposure Prophylaxis Adherence Monitoring. <i>Journal of Infectious Diseases</i> , 2015, 212, 1402-1406.	4.0	62
13	Metabolic Effects of Preexposure Prophylaxis With Coformulated Tenofovir Disoproxil Fumarate and Emtricitabine. <i>Clinical Infectious Diseases</i> , 2018, 67, 411-419.	5.8	50
14	Symptoms, Side Effects and Adherence in the iPrEx Open-Label Extension. <i>Clinical Infectious Diseases</i> , 2016, 62, 1172-1177.	5.8	40
15	Quality of Life Among Individuals with HIV Starting Antiretroviral Therapy in Diverse Resource-Limited Areas of the World. <i>AIDS and Behavior</i> , 2012, 16, 266-277.	2.7	34
16	Transgender Women in Clinical Trials of Pre-Exposure Prophylaxis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 72, S226-S229.	2.1	33
17	Self-reported Recent PrEP Dosing and Drug Detection in an Open Label PrEP Study. <i>AIDS and Behavior</i> , 2016, 20, 1535-1540.	2.7	33
18	The Role of Social Relationships in PrEP Uptake and Use Among Transgender Women and Men Who Have Sex with Men. <i>AIDS and Behavior</i> , 2018, 22, 3673-3680.	2.7	33

#	ARTICLE	IF	CITATIONS
19	Towards a fair consideration of PrEP as part of combination HIV prevention in Latin America. <i>Journal of the International AIDS Society</i> , 2016, 19, 21113.	3.0	32
20	Hepatitis B Infection and Association with Other Sexually Transmitted Infections Among Men Who Have Sex with Men in Peru. <i>American Journal of Tropical Medicine and Hygiene</i> , 2010, 83, 194-200.	1.4	29
21	The Safety of Tenofovir+Emtricitabine for HIV Pre-Exposure Prophylaxis (PrEP) in Individuals With Active Hepatitis B. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 71, 281-286.	2.1	25
22	Brief Report: Recovery of Bone Mineral Density After Discontinuation of Tenofovir-Based HIV Pre-exposure Prophylaxis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 76, 177-182.	2.1	25
23	The impact and cost-effectiveness of combined HIV prevention scenarios among transgender women sex-workers in Lima, Peru: a mathematical modelling study. <i>Lancet Public Health</i> , The, 2019, 4, e127-e136.	10.0	21
24	Brief Report: Cocaine Use and Pre-exposure Prophylaxis: Adherence, Care Engagement, and Kidney Function. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, 78-82.	2.1	18
25	Prevalence and Correlates of Human Herpesvirus 8 Infection Among Peruvian Men Who Have Sex With Men. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 49, 557-562.	2.1	14
26	Streamlining HIV Testing for HIV Preexposure Prophylaxis. <i>Journal of Clinical Microbiology</i> , 2015, 53, 179-183.	3.9	10
27	Impact of Estimated Pre-Exposure Prophylaxis (PrEP) Adherence Patterns on Bone Mineral Density in a Large PrEP Demonstration Project. <i>AIDS Research and Human Retroviruses</i> , 2019, 35, 788-793.	1.1	8
28	Health Survey in a Peruvian health system (ENSSA). <i>Revista De Saude Publica</i> , 2019, 53, 33.	1.7	5
29	HIV sero disclosure among men who have sex with men and transgender women on HIV pre-exposure prophylaxis. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2018, 30, 466-472.	1.2	4
30	Evaluating the impact of policies recommending PrEP to subpopulations of men and transgender women who have sex with men based on demographic and behavioral risk factors. <i>PLoS ONE</i> , 2019, 14, e0222183.	2.5	1
31	Reply to Boyd et al. <i>Clinical Infectious Diseases</i> , 2015, 60, 327-327.	5.8	0
32	International Sexual Partnerships May Be Shaped by Sexual Histories and Socioeconomic Status. <i>Sexually Transmitted Diseases</i> , 2017, 44, 306-309.	1.7	0